Konstantin Adamsky
Directeur/Membre du Conseil chez FILAMENT HEALTH CORP.
Profil
Konstantin Adamsky is the founder of Celleska Pty Ltd.
He is currently the Chief Executive Officer at Negev Labs and an Independent Director at Filament Health Corp.
Previously, he served as the Co-Chief Executive Officer & Director at Targia Pharmaceuticals Ltd.
in 2016.
He also held the position of Vice President-Operations & Technology at Levco Pharmaceuticals Ltd.
Additionally, he worked as the Vice President-Operations at Regenera Pharma Ltd.
from 2017 to 2020.
Dr. Adamsky obtained a doctorate degree from the Weizmann Institute of Science.
Postes actifs de Konstantin Adamsky
| Sociétés | Poste | Début |
|---|---|---|
| FILAMENT HEALTH CORP. | Directeur/Membre du Conseil | 23/08/2022 |
Anciens postes connus de Konstantin Adamsky
| Sociétés | Poste | Fin |
|---|---|---|
Regenera Pharma Ltd.
 Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | Directeur Général | 01/08/2017 |
| Levco Pharmaceuticals Ltd. | Directeur des opérations | - |
Formation de Konstantin Adamsky
| Weizmann Institute of Science | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| FILAMENT HEALTH CORP. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Regenera Pharma Ltd.
Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | Health Technology |
| Levco Pharmaceuticals Ltd. |
